Wedbush reiterated their outperform rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a research note published on Friday morning. Wedbush currently has a $253.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on the stock. Jefferies Group LLC started coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They set a buy rating and a $275.00 target price on the stock. Credit Suisse Group lifted their target price on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an outperform rating in a research report on Friday, May 5th. Oppenheimer Holdings, Inc. set a $200.00 target price on shares of Intercept Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, May 4th. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a hold rating to a buy rating and set a $136.00 target price on the stock in a research report on Tuesday, July 11th. Finally, Laidlaw upgraded shares of Intercept Pharmaceuticals from a sell rating to a hold rating and set a $115.00 target price on the stock in a research report on Friday, May 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of Buy and an average price target of $205.04.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 1.31% on Friday, hitting $109.44. 172,225 shares of the company were exchanged. The stock has a 50 day moving average price of $115.85 and a 200 day moving average price of $117.63. Intercept Pharmaceuticals has a one year low of $96.63 and a one year high of $172.95. The firm’s market cap is $2.75 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same period last year, the company earned ($3.14) EPS. The firm’s revenue was up 459.6% compared to the same quarter last year. On average, equities research analysts forecast that Intercept Pharmaceuticals will post ($14.05) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Given “Outperform” Rating at Wedbush” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/08/26/intercept-pharmaceuticals-inc-icpt-given-outperform-rating-at-wedbush.html.

In related news, CFO Sandip Kapadia sold 1,431 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.59, for a total transaction of $173,995.29. Following the transaction, the chief financial officer now owns 20,569 shares in the company, valued at approximately $2,500,984.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark Pruzanski sold 40,000 shares of the business’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the transaction, the chief executive officer now owns 611,718 shares in the company, valued at approximately $80,012,714.40. The disclosure for this sale can be found here. Insiders have sold a total of 47,208 shares of company stock worth $6,101,088 in the last quarter. 9.20% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $170,000. Pacer Advisors Inc. raised its stake in shares of Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Intercept Pharmaceuticals by 74.2% in the first quarter. Parametric Portfolio Associates LLC now owns 28,007 shares of the biopharmaceutical company’s stock worth $3,168,000 after buying an additional 11,933 shares during the period. Swiss National Bank raised its stake in shares of Intercept Pharmaceuticals by 2.2% in the first quarter. Swiss National Bank now owns 28,500 shares of the biopharmaceutical company’s stock worth $3,223,000 after buying an additional 600 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. Institutional investors own 83.05% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.